Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rosnilimab by AnaptysBio for Ulcerative Colitis: Likelihood of Approval
Rosnilimab is under clinical development by AnaptysBio and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II...
Rosnilimab by AnaptysBio for Rheumatoid Arthritis: Likelihood of Approval
Rosnilimab is under clinical development by AnaptysBio and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of AnaptysBio's Rosnilimab?
Rosnilimab is a monoclonal antibody commercialized by AnaptysBio, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...